Hudock Inc’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Hudock Inc’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-350	Closed	-$1.92K	–	611
2016 Q4	$2K	Buy	+350	New	+$1.91K	﹤0.01%	518

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Hudock Inc's KERX Position: Q1 2017 in Review

Hudock Inc sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2017, closing a stake of 350 shares — an estimated $1.92K sold.

Hudock Inc first reported a position in KERX in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 119 funds tracked by Wall St. Rank hold KERX as of Q1 2017.

Hudock Inc reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Hudock Inc sold 350 Keryx Biopharmaceuticals Inc shares in Q1 2017, an estimated $1.92K.
Hudock Inc first reported a position in Keryx Biopharmaceuticals Inc in Q4 2016 and held it in 1 quarter.
Hudock Inc's Keryx Biopharmaceuticals Inc position peaked at $2K in Q4 2016.
119 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2017.

Based on Hudock Inc's 13F filing for Q1 2017, filed 26 Apr 2017.